Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab long-term efficacy in Crohn's disease (M14-347)
NCT02185014Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2014
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc.. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02185014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185014.